Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic

  • L.H. Sehn
  • P. Kuruvilla
  • A. Christofides IMPACT Medicom Inc
  • J. Stakiw
Keywords: coronavirus; COVID-19; chronic lymphocytic leukemia

Abstract

The emergence of the coronavirus disease 2019 (COVID-19) pandemic has required a re-evaluation of treatment practices for clinicians caring for patients with chronic lymphocytic leukemia (CLL). The American Society for Hematology (ASH) has provided a series of recommendations for the treatment of patients with CLL during the pandemic, covering a range of topics including testing for COVID-19, CLL treatment initiation and selection, use of immunoglobulin therapy, in-person monitoring, and management of CLL patients with COVID-19. We summarize the ASH recommendations and discuss their applicability as guidelines for the treatment of CLL during the COVID-19 pandemic in Canada.


Published
2020-05-21
How to Cite
Sehn, L., Kuruvilla, P., Christofides, A., & Stakiw, J. (2020). Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic. Current Oncology, 27(3). https://doi.org/10.3747/co.27.6769
Section
Short Communication